See more : Setco Automotive Limited (SETCO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Repligen Corporation (RGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Repligen Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- S&B Foods Inc. (2805.T) Income Statement Analysis – Financial Results
- Ningbo Xianfeng New Material Co.,Ltd (300163.SZ) Income Statement Analysis – Financial Results
- Non-Standard Finance plc (NSF.L) Income Statement Analysis – Financial Results
- Hannong Chemicals Inc. (011500.KS) Income Statement Analysis – Financial Results
- Nordea Invest Stabile Aktier (NDISTABAKL1.CO) Income Statement Analysis – Financial Results
Repligen Corporation (RGEN)
About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 638.76M | 801.54M | 670.53M | 366.26M | 270.25M | 194.03M | 141.24M | 104.54M | 83.54M | 63.55M | 68.17M | 62.27M | 27.29M | 20.97M | 29.36M | 19.30M | 14.07M | 12.91M | 9.36M | 6.91M | 7.77M | 4.30M | 2.35M | 3.45M | 2.60M | 2.40M | 3.80M | 10.90M | 16.90M | 26.80M | 27.30M | 11.70M | 7.60M | 12.70M | 8.50M | 10.20M | 3.70M | 3.60M |
| Cost of Revenue | 323.54M | 345.83M | 279.28M | 156.63M | 119.10M | 85.95M | 67.05M | 47.12M | 35.25M | 28.02M | 25.16M | 27.17M | 7.12M | 5.51M | 6.78M | 6.16M | 3.61M | 3.55M | 3.89M | 3.25M | 3.48M | 1.99M | 1.12M | 782.23K | 400.00K | 300.00K | 300.00K | 100.00K | -1.10M | 1.50M | -500.00K | -200.00K | -600.00K | 10.50M | 7.60M | 7.20M | 4.40M | 2.60M |
| Gross Profit | 315.23M | 455.71M | 391.25M | 209.63M | 151.15M | 108.08M | 74.19M | 57.42M | 48.29M | 35.53M | 43.01M | 35.10M | 20.17M | 15.46M | 22.58M | 13.14M | 10.46M | 9.36M | 5.47M | 3.67M | 4.29M | 2.31M | 1.22M | 2.67M | 2.20M | 2.10M | 3.50M | 10.80M | 18.00M | 25.30M | 27.80M | 11.90M | 8.20M | 2.20M | 900.00K | 3.00M | -700.00K | 1.00M |
| Gross Profit Ratio | 49.35% | 56.85% | 58.35% | 57.23% | 55.93% | 55.70% | 52.53% | 54.93% | 57.80% | 55.90% | 63.09% | 56.36% | 73.92% | 73.74% | 76.92% | 68.08% | 74.32% | 72.50% | 58.47% | 53.02% | 55.22% | 53.67% | 52.15% | 77.33% | 84.62% | 87.50% | 92.11% | 99.08% | 106.51% | 94.40% | 101.83% | 101.71% | 107.89% | 17.32% | 10.59% | 29.41% | -18.92% | 27.78% |
| Research & Development | 42.72M | 43.94M | 34.27M | 20.18M | 19.45M | 15.77M | 8.67M | 7.36M | 5.74M | 5.61M | 7.34M | 10.49M | 12.53M | 14.16M | 12.77M | 7.24M | 5.92M | 5.16M | 5.04M | 6.48M | 5.23M | 5.36M | 5.79M | 3.75M | 1.80M | 1.40M | 1.40M | 12.30M | 31.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 65.69M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 0.00 | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 631.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 218.11M | 215.83M | 183.87M | 119.62M | 95.61M | 66.32M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 13.23M | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 4.71M | 4.16M | 2.53M | 2.49M | 2.48M | 1.60M | 1.30M | 2.40M | 4.90M | 4.70M | 42.10M | 37.40M | 23.60M | 15.60M | 3.90M | 3.70M | 3.60M | 3.60M | 3.00M |
| Other Expenses | 0.00 | -9.53M | -1.17M | -214.00K | -314.00K | 262.00K | -687.00K | -860.00K | -445.00K | 188.00K | -110.65K | 26.40K | 1.54B | 1.35M | 1.09M | -40.17M | 0.00 | 0.00 | 0.00 | 2.41M | 0.00 | 0.00 | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| Operating Expenses | 261.12M | 259.77M | 218.14M | 139.80M | 115.06M | 82.09M | 60.18M | 38.21M | 30.44M | 22.76M | 20.04M | 23.72M | 20.55M | 21.23M | 18.70M | -22.76M | 12.28M | 10.58M | 9.63M | 13.61M | 9.39M | 7.89M | 8.56M | 6.56M | 3.70M | 2.90M | 4.00M | 18.60M | 38.30M | 44.50M | 39.10M | 24.70M | 16.50M | 4.70M | 4.30M | 4.10M | 4.20M | 3.50M |
| Cost & Expenses | 584.66M | 605.60M | 497.42M | 296.44M | 234.16M | 168.04M | 127.23M | 85.33M | 65.69M | 50.79M | 45.21M | 50.89M | 27.67M | 26.74M | 25.48M | -16.60M | 15.90M | 14.13M | 13.52M | 16.86M | 12.87M | 9.88M | 9.68M | 7.34M | 4.10M | 3.20M | 4.30M | 18.70M | 37.20M | 46.00M | 38.60M | 24.50M | 15.90M | 15.20M | 11.90M | 11.30M | 8.60M | 6.10M |
| Interest Income | 0.00 | 6.98M | 176.00K | 1.74M | 5.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.03M | 1.16M | 12.71M | 12.13M | 9.29M | 6.71M | 6.44M | 3.77M | 32.00K | 49.96K | 49.85K | 56.71K | 26.17K | 1.97K | 2.96K | 2.96K | 0.00 | 696.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 68.56M | 50.99M | 38.45M | 27.07M | 20.87M | 15.78M | 10.45M | 5.33M | 4.59M | 4.02M | 3.11M | 3.51M | 1.67M | 1.38M | 1.08M | 824.63K | 539.03K | 398.43K | 756.26K | 886.71K | 802.23K | 257.54K | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| EBITDA | 127.77M | 246.93M | 211.56M | 101.62M | 58.43M | 41.77M | 24.14M | 24.55M | 22.44M | 15.16M | 26.13M | 14.84M | -30.47K | 1.66M | -3.52M | 6.85M | 36.72M | -1.83M | -1.22M | -2.23M | -8.66M | -4.29M | -5.32M | -7.06M | -4.04M | -2.46M | -615.02K | -2.80M | -6.40M | -17.70M | -16.80M | -9.60M | -11.70M | -7.40M | -1.70M | -2.80M | -600.00K | -4.30M |
| EBITDA Ratio | 20.00% | 23.03% | 25.64% | 19.01% | 13.24% | 13.53% | 9.43% | 17.56% | 20.83% | 20.38% | 33.52% | 18.32% | 4.77% | -20.92% | 16.88% | -28.53% | -15.87% | -15.42% | -48.96% | -101.69% | -62.40% | -149.65% | -388.18% | -105.49% | -7.69% | -25.00% | -10.53% | -25.69% | -37.87% | -62.69% | -35.16% | -100.00% | -132.89% | -14.17% | -32.94% | -21.57% | 310.81% | -86.11% |
| Operating Income | 54.58M | 133.61M | 133.50M | 42.54M | 14.90M | 25.99M | 14.01M | 15.97M | 13.76M | 10.69M | 22.87M | 11.08M | -374.07K | -5.77M | 3.88M | 35.89M | -1.83M | -1.22M | -4.16M | -9.94M | -5.09M | -5.58M | -7.33M | -3.89M | -1.50M | -800.00K | -500.00K | -7.80M | -20.30M | -19.20M | -11.30M | -12.80M | -8.30M | -2.50M | -3.40M | -1.10M | -4.90M | -2.50M |
| Operating Income Ratio | 8.54% | 16.67% | 19.91% | 11.62% | 5.51% | 13.39% | 9.92% | 15.28% | 16.48% | 16.82% | 33.55% | 17.80% | -1.37% | -27.50% | 13.21% | 186.00% | -12.97% | -9.45% | -44.46% | -143.77% | -65.55% | -129.67% | -312.46% | -112.74% | -57.69% | -33.33% | -13.16% | -71.56% | -120.12% | -71.64% | -41.39% | -109.40% | -109.21% | -19.69% | -40.00% | -10.78% | -132.43% | -69.44% |
| Total Other Income/Expenses | 9.56M | -5.53M | -13.71M | -10.61M | -9.93M | -4.55M | -6.76M | -4.28M | -341.00K | 447.58K | 140.82K | -108.34K | -2.35M | 5.72M | 868.07K | 1.89M | 39.76M | 936.07K | 1.92M | 1.18B | 5.40M | 1.12M | 2.05M | 3.52M | 1.86M | 1.96M | 315.02K | 500.00K | 7.80M | 800.00K | 7.90M | 0.00 | 7.10M | 5.90M | 2.50M | 3.70M | 1.10M | 3.50M |
| Income Before Tax | 64.13M | 219.14M | 153.54M | 59.22M | 26.15M | 21.44M | 7.25M | 11.69M | 13.42M | 11.14M | 23.01M | 11.27M | -43.51K | -4.90M | 5.77M | 37.93M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Income Before Tax Ratio | 10.04% | 27.34% | 22.90% | 16.17% | 9.68% | 11.05% | 5.13% | 11.18% | 16.07% | 17.53% | 33.76% | 18.10% | -0.16% | -23.36% | 19.66% | 196.59% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| Income Tax Expense | 22.56M | 33.18M | 25.25M | -709.00K | 4.74M | 4.82M | -21.11M | 11.00K | 4.08M | 2.97M | 6.92M | -2.88M | -330.56K | -834.77K | 26.70K | 827.47K | 889.26K | -696.86K | 2.98M | 9.55M | 4.54M | 4.46M | 5.28M | 3.82M | 2.50M | 800.00K | 500.00K | 11.50M | 32.00M | 19.50M | 11.30M | 12.80M | 5.70M | 2.40M | 3.30M | -300.00K | 20.70M | 1.40M |
| Net Income | 41.58M | 185.96M | 128.29M | 59.93M | 21.41M | 16.62M | 28.35M | 11.68M | 9.35M | 8.17M | 16.09M | 14.16M | -43.51K | -4.06M | 5.75M | 37.11M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Net Income Ratio | 6.51% | 23.20% | 19.13% | 16.36% | 7.92% | 8.56% | 20.07% | 11.17% | 11.19% | 12.86% | 23.61% | 22.73% | -0.16% | -19.38% | 19.57% | 192.30% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| EPS | 0.75 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 | 0.28 | 0.25 | 0.51 | 0.46 | 0.00 | -0.13 | 0.19 | 1.20 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.75 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| EPS Diluted | 0.74 | 3.24 | 2.24 | 1.11 | 0.44 | 0.37 | 0.72 | 0.34 | 0.28 | 0.25 | 0.50 | 0.45 | 0.00 | -0.13 | 0.18 | 1.18 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.74 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| Weighted Avg Shares Out | 55.72M | 55.46M | 55.02M | 52.55M | 48.34M | 43.77M | 38.23M | 33.57M | 32.88M | 32.50M | 31.67M | 30.91M | 30.78M | 30.75M | 30.96M | 30.83M | 30.38M | 30.13M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.37M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
| Weighted Avg Shares Out (Dil) | 56.38M | 57.46M | 57.26M | 53.89M | 49.21M | 45.47M | 39.15M | 34.10M | 33.58M | 33.26M | 32.41M | 31.25M | 30.78M | 30.75M | 31.29M | 31.32M | 30.38M | 30.69M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.53M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare conference being held January 8-11 in San...
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024...
Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the...
Repligen Announces Publication of the Company's 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the...
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences.
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry's first holder-free, self-contained Tangential Flow Filtration (TFF) device.
Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat
Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023.
Source: https://incomestatements.info
Category: Stock Reports